Patents by Inventor Daniel John Lightwood

Daniel John Lightwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them
    Patent number: 10935553
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 2, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Daniel John Lightwood, Rebecca Jayne Munro
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20200407436
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
    Publication number: 20200377578
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
  • ANTIBODY MOLECULES WHICH BIND TNF ALPHA
    Publication number: 20200291104
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 17, 2020
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, Dave Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
    Patent number: 10775385
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Wootton
  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 10766956
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
    Publication number: 20200277366
    Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
  • Neutralising antibodies to the major exotoxins TCDA and TCDB of
    Patent number: 10752676
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: August 25, 2020
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
  • ANTIBODY EPITOPE
    Publication number: 20190330327
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: December 13, 2017
    Publication date: October 31, 2019
    Inventors: Alastair David Griffiths LAWSON, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO, James Philip O'CONNELL, John Robert PORTER
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20190330321
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 31, 2019
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • NOVEL TNFalpha STRUCTURE FOR USE IN THERAPY
    Publication number: 20180231562
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 16, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON
  • ANTIBODY
    Publication number: 20180171008
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: October 22, 2015
    Publication date: June 21, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON
  • ANTIBODY EPITOPE
    Publication number: 20180172701
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: October 22, 2015
    Publication date: June 21, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Tracy Lynn ARAKAKI, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON
  • Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
    Patent number: 9957320
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13
    Publication number: 20160289323
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: June 13, 2016
    Publication date: October 6, 2016
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
    Patent number: 9394361
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 19, 2016
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
    Publication number: 20160159922
    Abstract: Novel antibodies or binding fragments thereof, which exhibit specific binding to citrullinated epitopes are disclosed, as well as pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in diagnosis, in prognostics, treatment and/or alleviation of rheumatoid arthritis, as well as processes for generating and preparing said antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 9, 2016
    Inventors: Lars KLARESKOG, Vivianne MALMSTRÖM, Johanna Maria ÅKERBLÖM STEEN, Daniel John LIGHTWOOD, Stephen Edward RAPECKI
  • NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
    Publication number: 20140348844
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox
  • ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13
    Publication number: 20140178387
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 26, 2014
    Applicant: UCB Pharma S.A.
    Inventors: NEIL GOZZARD, ALASTAIR DAVID GRIFFITHS LAWSON, DANIEL JOHN LIGHTWOOD, ROGER THOMAS PALFRAMAN, BRYAN JOHN SMITH, KERRY LOUISE TYSON
  • Antibody molecules having binding specificity for human IL-13
    Patent number: 8691233
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: April 8, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson